Quarterly ResultMay 7, 2026, 07:07 AM
Insmed Q1 Product Revenue $306M; Net Loss Narrows to $164M
AI Summary
Insmed reported a significant increase in product revenues for Q1 2026, reaching $305.96 million, up from $92.82 million in Q1 2025. The company's net loss narrowed to $163.56 million, or $(0.76) per share, compared to a net loss of $256.58 million, or $(1.42) per share, in the prior year period. This revenue growth was primarily driven by the commercial launch of BRINSUPRI, which generated $207.18 million in US sales. Despite improved financial performance, Insmed expects to continue incurring operating losses due to ongoing research and development activities and commercialization efforts for its product pipeline.
Key Highlights
- Product revenues, net increased to $305.96 million in Q1 2026 from $92.82 million in Q1 2025.
- Net loss narrowed to $163.56 million in Q1 2026 from $256.58 million in Q1 2025.
- Basic and diluted net loss per share improved to $(0.76) in Q1 2026 from $(1.42) in Q1 2025.
- BRINSUPRI US revenue was $207.18 million in Q1 2026, following its August 2025 US approval.
- Cash and cash equivalents stood at $582.19 million as of March 31, 2026.
- Total operating expenses increased to $459.28 million in Q1 2026 from $340.96 million in Q1 2025.
- A gain of $46.96 million was recorded from the change in fair value of contingent consideration in Q1 2026.